Supplemental Material

Relation of Insulin Resistance to Brain Glucose Metabolism in Fasting and Hyperinsulinemic States: A Systematic Review and Meta-Analysis

Table of Contents

Supplemental Table S1. Specific search terms used in each database
Supplemental Fig. S1. Forest plot of brain regions stratified by metabolic condition (fasting vs insulin stimulation)
Supplemental Fig. S2. Flow chart of study inclusion
Supplemental Table S2. Overview of excluded reports during full-text screening5
Supplemental Table S3. Quality assessment of included studies in the meta-analysis6
Supplemental Fig. S3. Forest plot of all 24 studies stratified by metabolic condition (fasting vs insulin stimulation)
Supplemental Fig. S4. Funnel plots and Egger's test for identification of publication bias8
Supplemental Fig. S5. Forest plot of quantification method used for estimating brain glucose metabolism stratified by metabolic condition (fasting vs insulin stimulation)9
Supplemental Fig. S6. Assessments of influential studies by the leave-one-out method10
Fig. S6A All studies (Fasting)
Fig. S6B All studies (insulin stim.)
Fig. S6C T2D/PreD (Fasting)
Fig. S6D OW/Obese (Fasting)
Fig. S6E Other IR-related conditions (Fasting)
Fig. S6F T2D/PreD (insulin stim.)
oferences 19

Supplemental Table S1. Specific search terms used in each database

Database: PubMed

(("fluorodeoxyglucose f18" [MeSH] OR "fdg" [Journal] OR "fdg" [All Fields] "cmrg*" [All Fields] OR "Cerebral glucose metabolism" [All Fields] OR "Brain glucose uptake" [All Fields])

("diabetes mellitus, type 2"[MeSH] OR "overweight" [MeSH] OR "Polycystic ovary syndrome" [MeSH] OR "metabolic syndrome" [MeSH] OR "Insulin resistance" [MeSH] OR "Type 2 diabetes" [All Fields] OR ("obeses" [All Fields] OR "obesity" [MeSH] OR "obesity" [All Fields] OR "obese" [All Fields] OR "obesities" [All Fields] OR "obesity s" [All Fields])OR ("overweight" [MeSH] OR "overweight" [All Fields] OR "overweighted" [All Fields]" OR "overweightedness" [All Fields] OR "overweights" [All Fields] OR Polycystic ovary syndrome" [All Fields] OR "Polycystic ovarian syndrome" [All Fields] OR "PCOS" [All Fields] OR "Metabolic syndrome" [All Fields] OR "Insulin resistance" [All Fields] OR ("prediabetic state" [MeSH] OR ("prediabetic" [All Fields] AND "state" [All Fields]) OR "prediabetic state" [All Fields] OR "prediabetes" [All fields] OR "prediabetics" [All Fields]) OR "Insulin sensitivity" [All fields] OR "impaired glucose tolerance" [All Fields] OR "impaired fasting glucose" [All Fields])) AND

("Brain" [MeSH] OR "Brain" [All Fields] OR "Brains" [All Fields], OR "brain s" [All Fields] OR "cerebrally" [All Fields] OR "cerebrum" [MeSH] OR "cerebrum" [All Fields] OR "cerebral[All Fields]")

Database: Embase

('exp Fluorodeoxyglucose f 18/' OR 'FDG.mp' OR 'cerebral glucose metabolism.mp' OR 'brain glucose uptake.mp' OR 'CMRg*.mp')

AND

('exp non insulin dependent diabetes mellitus/' OR 'Type 2 diabetes.mp.' OR 'exp obesity/' OR 'Obesity.mp.' OR 'Overweight.mp.' OR 'exp ovary polycystic disease/' OR 'Polycystic ovary syndrome.mp.' OR Polycystic ovarian syndrome.mp.' OR 'PCOS.mp.' OR 'Exp metabolic syndrome X/' OR 'Metabolic syndrome.mp.' OR 'Exp insulin resistance/' OR 'insulin resistance.mp.' OR 'Prediabetes.mp.' OR 'exp insulin sensitivity/' OR 'insulin sensitivity.mp.' OR 'exp impaired glucose tolerance/' OR 'impaired glucose tolerance.mp.' OR 'impaired fasting glucose.mp.')

AND

('exp brain/' OR 'Cerebral.mp.' OR 'brain.mp.')

Database: CENTRAL

("Fluorodeoxyglucose F18"[MeSH] OR FDG[All text] OR CMRg*[All text] OR "Cerebral glucose metabolism"[All text] OR "Brain glucose uptake"[All text])

("Diabetes Mellitus, Type 2" [MeSH] OR "Type 2 diabetes" [All text] OR "Overweight" [MeSH] OR Overweight[All text] OR Obesity[All text] OR "Polycystic Ovary Syndrome"[MeSH] OR "Polycystic ovary syndrome"[All text] OR "Polycystic ovarian syndrome"[All text] OR PCOS[All text] OR "Metabolic syndrome" [MeSH] OR "Metabolic syndrome" [All text] OR "Insulin resistance" [MeSH] OR "Insulin resistance"[All text] OR Prediabetes[All text] OR "Insulin sensitivity"[All text] OR "Impaired glucose tolerance"[All text] OR "Impaired fasting glucose"[All text]) AND

("Brain"[MeSH] OR Brain[All text] OR Cerebral[All text])

Note: The argument 'explode all trees' was applied for all [MeSH] terms. In [All text] arguments word variations have been searched.

Database: Web of Science

((((ALL=("Flourodeoxyglucose F18")) OR ALL=(FDG)) OR ALL=(CMRg*))

OR ALL=("cerebral glucose metabolism")) OR ALL=("brain glucose uptake")

AND

ovary syndrome")) OR ALL=("Polycystic ovarian syndrome")) OR ALL=(PCOS)) OR ALL=("Metabolic syndrome")) OR ALL=("Insulin resistance")) OR ALL=(Prediabetes)) OR ALL=("Insulin sensitivity")) OR ALL=("impaired glucose tolerance")) OR ALL=("impaired fasting glucose") AND

(ALL=(Brain)) OR ALL=(Cerebral)


Note: All searches were conducted on February 24th, 2022.

Supplemental Fig. S1. Forest plot of brain regions stratified by metabolic condition (fasting vs insulin stimulation)

Brain regions	Number of studies	Interaction P-value	Hedges' g [95%-CI]	SMD
Fasting				
Whole brain	12	0.56	-0.33 [-0.62; -0.04]	
Frontal	14		-0.51 [-0.78; -0.24]	⊞
Temporal	8		-0.24 [-0.51; 0.03]	⊞
Parietal	10		-0.29 [-0.73; 0.15]	
Occipital	5		-0.14 [-0.84; 0.55]	
Subcortical	9		-0.38 [-0.52; -0.25]	€
Cingulate	3		-0.48 [-2.00; 1.04]	
Cerebellum	5		0.09 [-0.77; 0.95]	-
Hyperinsu	ılinemic clan	np		
Whole brain	2	0.76	1.49 [-1.96; 4.95]	
Frontal	3		1.55 [-0.98; 4.08]	- 1
Temporal	3		1.52 [-0.85; 3.89]	
Parietal	3		1.81 [-1.61; 5.22]	- 1
Occipital	3		1.72 [-1.29; 4.72]	
Subcortical	2		1.14 [-1.57; 3.84]	
Cerebellum	4		2.44 [-0.62; 5.49]	-4 -2 0 2 4

Note: Summary of standardized mean differences of brain glucose metabolism within each selected brain region. Reports from insula, midbrain and pons were excluded due to low study numbers.

Supplemental Fig. S2. Flow chart of study inclusion



Supplemental Table S1. Overview of excluded reports during full-text screening.

Studies excluded from systematic review

Reason: Wrong population or comparator group: (1-15)

Reason: Wrong outcome: (16-23) Reason: Conference abstract: (24-26)

Reason: Review: (27)

Further exclusions

Reason: Overlapping study population:

Li 2016: (28-33)Eriksson 2021: (34; 35)Garcia-Casares 2014: (36)

Képes 2021: (37)

· Reports including pooled data: (38-41)

Reason: Association not reported and not available on request: (42-46)

Reason: Test condition not relevant: (47)

Studies excluded from meta-analysis

Reason: Insufficient available data for meta-analysis: (48-51) Reason: Study design not relevant for meta-analysis: (52-54)

Note: References are found at the end of the supplemental material.

Supplemental Table S3. Quality assessment of included studies in the meta-analysis

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Risk
Baker, 2011									Low
Büsing, 2013			0	0					Moderate
Castellano, 2015									Low
Chen, 2022				0					Low
Eriksson, 2021									Low
Femminella, 2021									Low
GarcÃ-a-Casares, 2014									Low
Hirvonen, 2011									Moderate
Honkala, 2018				\bigcirc					Low
Ishibashi, 2015									Moderate
Ishibashi, 2017				0					Moderate
Képes, 2021			\bigcirc	\bigcirc					Moderate
Latva-Rasku 2018				0					Low
Li, 2016			\bigcirc	\bigcirc					Moderate
Li, 2022									Low
Nam, 2017									Low
Nummenmaa, 2012			\bigcirc	\bigcirc					Moderate
Orava, 2014						0			Moderate
Roberts, 2014			\bigcirc	\bigcirc					Moderate
Tuulari, 2013						\circ			Low
Wang, 2001									Low
Wang, 2002									Low
Waqas, 2019									Low
Willette, 2015				0					Low


The Joanna Briggs Institute (JBI) Critical Appraisal tool for Analytical Cross-Sectional studies was used for quality assessment. Q1: Were the criteria for inclusion in the sample clearly defined? Q2: Were the study subjects and the setting described in detail? Q3: Was the exposure measured in a valid and reliable way? Q4: Were objective, standard criteria used for measurement of the condition? Q5: Were confounding factors identified? Q6: Were strategies to deal with confounding factors stated? Q7: Were the outcomes measured in a valid and reliable way? Q8: Was appropriate statistical analysis used? Questions were answered by 'yes' ○, 'no' ○, 'unclear' ○, or 'not applicable' ○. Scoring was based on Yes-answers, and <50%, 50-69%, ≥70% were considered as 'High', 'Moderate', and 'Low' risk studies, respectively. In Q2 a lack of recruitment period description was not considered sufficient to score as 'no'. In most studies exposure and condition (Q3 and Q4) were identical. In Q5 and Q6 age, sex, and BMI were considered important confounders. Q7 was only registered as 'yes' if a quantitative methodology was applied.

Supplemental Fig. S3. Forest plot of all 24 studies stratified by metabolic condition (fasting vs insulin stimulation)

Author, year (study population)	Total N	Hedges' g [95%-CI]	SMD
Fasting			
Busing, 2013 (T2D)	90	-1.13 [-1.60; -0.66]	
Li, 2016 (T2D, AD)	203	-0.10 [-0.64; 0.44]	- 🖫 -
Li, 2016 (T2D, MCI)	1034	-0.36 [-0.57; -0.15]	⊞
Li, 2016 (T2D, CH)	429	-0.41 [-0.77; -0.04]	
Li, 2022 (T2D, elderly)	69	-1.13 [-1.64; -0.62]	
Li, 2022 (T2D, middleage)	68	-0.33 [-0.81; 0.15]	-
Baker, 2011 (T2D/PreD)	23	-1.56 [-2.60; -0.53]	
Garcia-Casares, 2014 (T2D/PreD)	25	-2.19 [-3.36; -1.02]	
Kepes, 2021 (T2D/PreD)	96	-1.14 [-1.58; -0.71]	
Roberts, 2014 (T2D/PreD)	749	-0.52 [-0.70; -0.34]	⊞
Waqas, 2019 (T2D/PreD)	119	-0.39 [-0.79; 0.02]	
Hirvonen, 2011 (IGT)	22	-0.05 [-0.90; 0.80]	
Ishibashi, 2015b (IFG)	51	-0.92 [-1.51; -0.33]	
Tuulari, 2013 (morbidly obese, incl.T2D/PreD)	29	0.35 [-0.50; 1.21]	
Wang, 2001 (morbidly obese)	20	0.65 [-0.25; 1.56]	-
Wang, 2002 (morbidly obese)	30	0.91 [0.11; 1.71]	
Orava, 2014 (OW/Obese)	41	-0.62 [-1.25; 0.02]	- D
Nam, 2017 (MetS)	264	-0.69 [-1.01; -0.38]	
Castellano, 2015 (PCOS)	18	-0.75 [-1.74; 0.24]	
Femminella, 2021 (AD)	130	-0.54 [-0.89; -0.18]	
Chen, 2022 (CH, incl. T2D 13%)	189	-0.24 [-0.53; 0.05]	
Willette, 2015 (older middle-aged, CH)	150	-0.25 [-0.57; 0.07]	
Ishibashi, 2017 (NW, CH)	59	0.19 [-0.32; 0.70]	-
Total (95% CI)		-0.51 [-0.78; -0.25]	•
Heterogeneity: $Tau^2 = 0.19$; $Chi^2 = 72.42$, $df = 2$	20 (P < 0.00)1); I ² = 72%	
Hyperinsulinemic clamp			
Eriksson, 2021 (T2D/PreD)	41	1.33 [0.59; 2.06]	
Honkala, 2018 (T2D/PreD)	21	1.94 [0.74; 3.13]	
Hirvonen, 2011 (IGT)	22	0.98 [0.07; 1.89]	
Tuulari, 2013 (morbidly obese, incl.T2D/PreD)	29	2.84 [1.69; 4.00]	
Nummenmaa, 2012 (morbidly obese)	30	1.33 [0.52; 2.13]	
Latva-Rasku, 2018 (p.P50T/AKT2 carriers)	45	1.05 [0.42; 1.68]	-
Total (95% CI)		1.44 [0.79; 2.09]	
Heterogeneity: $Tau^2 = 0.11$; $Chi^2 = 8.83$, $df = 5$	(P = 0.12);	$I^2 = 43\%$	
Total (95% CI)		-0.11 [-0.54; 0.31]	
Heterogeneity: $Tau^2 = 0.91$; $Chi^2 = 188.42$, $df =$	26 (P < 0.0		1 1
Test for subgroup differences: Chi ² = 47.39, df		-4	4 -2 0 2

Note: As the studies by Hirvonen 2011 and Tuulari 2013 provided data on brain glucose metabolism during both fasting and hyperinsulinemic clamp, the two studies were excluded among fasting studies to avoid overlapping study population affecting estimates. The standardized mean differences (SMD) changes slightly when the two studies were excluded among the studies performed under hyperinsulinemic clamps, such that SMD was -0.47 SD (95%-CI, -0.73 to -0.22) during fasting and 1.28 SD (95%-CI, 0.81 to 1.76) during hyperinsulinemic clamp.

Supplemental Fig. S4. Funnel plots and Egger's test for identification of publication bias



Supplemental Fig. S5. Forest plot of quantification method used for estimating brain glucose metabolism stratified by metabolic condition (fasting vs insulin stimulation)

Quantification method	Number of studies	Interaction P-value	Hedges' g [95%-CI]	SMD
Fasting				
Quantitative	7	0.05	-0.04 [-0.65; 0.56]	-
Semiquantitative	16		-0.59 [-0.86; -0.33]	■
Hyperinsulinemic clamp				
Quantitative	6		1.44 [0.79; 2.09]	-
Fasting - Quantitative				
Type 2 diabetes/Prediabetes	1	0.03	-0.05 [-0.90; 0.80]	-
Overweight/Obesity	4		0.29 [-0.81; 1.39]	-
Other insulin resistance-related conditions	2		-0.56 [-1.43; 0.31]	
Fasting - Semiquantitative				
Type 2 diabetes/Prediabetes	12	0.05	-0.72 [-1.04; -0.40]	
Other insulin resistance-related conditions	4		-0.28 [-0.83; 0.26]	=
Hyperinsulinemic clamp - Quanti	tative			
Type 2 diabetes/Prediabetes	3	0.46	1.33 [0.33; 2.32]	
Overweight/Obesity	2		2.03 [-7.58; 11.63]	←
Other insulin resistance-related conditions	1		1.05 [0.42; 1.68]	-4 -2 0 2

Note: Summary of standardized mean differences of brain glucose metabolism for quantitative and semi-quantitative studies.

Supplemental Fig. S6. Assessments of influential studies by the leave-one-out method

Fig. S6A All studies (Fasting)




Fig. S6B All studies (insulin stim.)




Fig. S6C T2D/PreD (Fasting)




Fig. S6D OW/Obese (Fasting)




Fig. S6E Other IR-related conditions (Fasting)





Fig. S6F T2D/PreD (insulin stim.)



Note: Effect sizes when applying the leave-one-out method using the 'dmetar' R package (v.0.1.0) to find influential cases.

Supplemental Table S4. References of studies included in the systematic-review and meta-analysis

- 1. Baker LD, Cross DJ, Minoshima S, Belongia D, Stennis Watson G, Craft S. Insulin resistance and alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Archives of Neurology 2011;68(1):51-57
- 2. Büsing KA, Schönberg SO, Brade J, Wasser K. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT. Nucl Med Biol 2013;40:206-213
- 3. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, Larson SM, Roth J. Brain glucose metabolism in noninsulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic glucose clamp. J Clin Endocrinol Metab 1990;71:1602-1610 4. Eriksson JW, Visvanathar R, Kullberg J, Strand R, Skrtic S, Ekström S, Lubberink M, Lundqvist MH, Katsogiannos P, Pereira MJ, Ahlström H. Tissue-specific glucose partitioning and fat content in prediabetes and type 2 diabetes: whole-body PET/MRI during hyperinsulinemia. Eur J Endocrinol 2021;184:879-889 5. García-Casares N, Berthier ML, Jorge RE, Gonzalez-Alegre P, Gutiérrez Cardo A, Rioja Villodres J, Acion L, Ariza Corbo MJ, Nabrozidis A, García-Arnés JA, González-Santos P. Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. J Alzheimers Dis 2014;40:375-386
- 6. Hirvonen J, Virtanen KA, Nummenmaa L, Hannukainen JC, Honka MJ, Bucci M, Nesterov SV, Parkkola R, Rinne J, Iozzo P, Nuutila P. Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes 2011;60(2):443-447
- 7. Honkala SM, Johansson J, Motiani KK, Eskelinen JJ, Virtanen KA, Loyttyniemi E, Knuuti J, Nuutila P, Kalliokoski KK, Hannukainen JC. Short-term interval training alters brain glucose metabolism in subjects with insulin resistance. Journal of Cerebral Blood Flow and Metabolism 2018;38(10):1828-1838 8. Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. J Nucl Med 2015;56:229-233
- 9. Képes Z, Aranyi C, Forgács A, Nagy F, Kukuts K, Hascsi Z, Esze R, Somodi S, Káplár M, Varga J, Emri M, Garai I. Glucose-level dependent brain hypometabolism in type 2 diabetes mellitus and obesity. Eur J Hybrid Imaging 2021;5:3
- 10. Li W, Risacher SL, Huang E, Saykin AJ. Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort. Neurology 2016;87:595-600
- 11. Li YL, Wu JJ, Ma J, Li SS, Xue X, Wei D, Shan CL, Hua XY, Zheng MX, Xu JG. Alteration of Individual Metabolic Network of Brain Based on Jensen-Shannon Divergence Similarity Estimation in the Elderly with Type 2 Diabetes Mellitus. Diabetes 2022;
- 12. Roberts RO, Knopman DS, Cha RH, Mielke MM, Pankratz VS, Boeve BF, Kantarci K, Geda YE, Jack CR, Jr., Petersen RC, Lowe VJ. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med 2014;55:759-764
- 13. Waqas K, van Haard PMM, Postema JWA, Schweitzer DH. Diabetes Mellitus-Related Fractional Glucose Uptake in Men and Women Imaged With (18)F-FDG PET-CT. J Endocr Soc 2019;3:773-783
- 14. Almby KE, Lundqvist MH, Abrahamsson N, Kvernby S, Fahlström M, Pereira MJ, Gingnell M, Karlsson FA, Fanni G, Sundbom M, Wiklund U, Haller S, Lubberink M, Wikström J, Eriksson JW. Effects of Gastric Bypass Surgery on the Brain: Simultaneous Assessment of Glucose Uptake, Blood Flow, Neural Activity, and Cognitive Function During Normo- and Hypoglycemia. Diabetes 2021;70:1265-1277
- 15. Nummenmaa L, Hirvonen J, Hannukainen JC, Immonen H, Lindroos MM, Salminen P, Nuutila P. Dorsal striatum and its limbic connectivity mediate abnormal anticipatory reward processing in obesity. PLoS One 2012;7:e31089
- 16. Orava J, Nummenmaa L, Noponen T, Viljanen T, Parkkola R, Nuutila P, Virtanen KA. Brown adipose tissue function is accompanied by cerebral activation in lean but not in obese humans. J Cereb Blood Flow Metab 2014;34:1018-1023
- 17. Tuulari JJ, Karlsson HK, Hirvonen J, Hannukainen JC, Bucci M, Helmio M, Ovaska J, Soinio M, Salminen P, Savisto N, Nummenmaa L, Nuutila P. Weight loss after bariatric surgery reverses insulininduced increases in brain glucose metabolism of the morbidly obese. Diabetes 2013;62(8):2747-2751 18. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. Brain dopamine and obesity. Lancet 2001;357:354-357
- 19. Wang GJ, Volkow ND, Felder C, Fowler JS, Levy AV, Pappas NR, Wong CT, Zhu W, Netusil N. Enhanced resting activity of the oral somatosensory cortex in obese subjects. Neuroreport 2002;13:1151-1155

- 20. Wang GJ, Shokri Kojori E, Yuan K, Wiers CE, Manza P, Wong CT, Fowler JS, Volkow ND. Inhibition of food craving is a metabolically active process in the brain in obese men. Int J Obes (Lond) 2020;44:590-600
- 21. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK, Amiel SA. Attenuation of insulinevoked responses in brain networks controlling appetite and reward in insulin resistance: The cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006;55(11):2986-2992
- 22. Castellano CA, Baillargeon JP, Nugent S, Tremblay S, Fortier M, Imbeault H, Duval J, Cunnane SC. Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance. PLoS One 2015;10:e0144116
- 23. Chen Y, Qiu C, Yu W, Shao X, Zhou M, Wang Y, Shao X. The relationship between brain glucose metabolism and insulin resistance in subjects with normal cognition a study based on 18F-FDG PET. Nuclear medicine communications 2022;43:275-283
- 24. Ennis GE, Kohli A, Jonaitis EM, Betthauser TJ, Oh JM, Taylor CE, Chin N, Koscik RL, Christian BT, Asthana S, Johnson SC, Bendlin BB. The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiol Aging 2021;105:174-185
- 25. Femminella GD, Livingston NR, Raza S, van der Doef T, Frangou E, Love S, Busza G, Calsolaro V, Carver S, Holmes C, Ritchie CW, Lawrence RM, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood B, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Passmore AP, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Tan T, Holscher C, Harrison J, Brooks DJ, Ballard C, Edison P. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? Alzheimers Res Ther 2021;13:47
- 26. Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K. Effects of glucose, insulin, and insulin resistance on cerebral 18F-FDG distribution in cognitively normal older subjects. PLoS One 2017;12:e0181400 27. Kantonen T, Pekkarinen L, Karjalainen T, Bucci M, Kalliokoski K, Haaparanta-Solin M, Aarnio R, Dickens AM, von Eyken A, Laitinen K, Houttu N, Kirjavainen AK, Helin S, Hirvonen J, Rönnemaa T, Nuutila P, Nummenmaa L. Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability. Int J Obes (Lond) 2022;46:400-407
- 28. Latva-Rasku A, Honka MJ, Stančáková A, Koistinen HA, Kuusisto J, Guan L, Manning AK, Stringham H, Gloyn AL, Lindgren CM, Collins FS, Mohlke KL, Scott LJ, Karjalainen T, Nummenmaa L, Boehnke M, Nuutila P, Laakso M. A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study. Diabetes 2018;67:334-342
- 29. Nam HY, Jun S, Pak K, Kim IJ. Concurrent Low Brain and High Liver Uptake on FDG PET Are Associated with Cardiovascular Risk Factors. Korean J Radiol 2017;18:392-401
- 30. Osborne MT, Ishai A, Hammad B, Tung B, Wang Y, Baruch A, Fayad ZA, Giles JT, Lo J, Shin LM, Grinspoon SK, Koenen KC, Pitman RK, Tawakol A. Amygdalar activity predicts future incident diabetes independently of adiposity. Psychoneuroendocrinology 2019;100:32-40
- 31. Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, Okonkwo OC, La Rue A, Hermann BP, Koscik RL, Jonaitis EM, Sager MA, Asthana S. Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA Neurol 2015;72:1013-1020

References

- 1. Annane D, Fiorelli M, Mazoyer B, Pappata S, Eymard B, Radvanyi H, Junien C, Fardeau M, Merlet P, Gajdos P, Syrota A, Sansom Y, Duboc D. Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon. Neuromuscul Disord 1998;8:39-45
- 2. Burns CM, Kaszniak AW, Chen K, Lee W, Bandy DJ, Caselli RJ, Reiman EM. Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions. J Alzheimers Dis 2018;62:833-840
- 3. Ciudin A, Simó-Servat O, Hernández C, Arcos G, Diego S, Sanabria Á, Sotolongo Ó, Hernández I, Boada M, Simó R. Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease. Diabetes 2017;66:3098-3104 4. Daniele G, Iozzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Gastaldelli A. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes 2015;64:3406-3412
- 5. Guzzardi MA, Garelli S, Agostini A, Filidei E, Fanelli F, Giorgetti A, Mezzullo M, Fucci S, Mazza R, Vicennati V, Iozzo P, Pagotto U. Food addiction distinguishes an overweight phenotype that can be reversed by low calorie diet. Eur Eat Disord Rev 2018;26:657-670
- 6. Huang YC, Hsu CC, Lin WC, Yin TK, Huang CW, Wang PW, Chang HH, Chiu NT. Effects of metformin on the cerebral metabolic changes in type 2 diabetic patients. ScientificWorldJournal 2014;2014:694326
- 7. Kim JM, Jang M, Kim EH, Kim M, Choi SJ, Kim K, Pak K, Jeon YK, Kim SS, Kim BH, Kim SJ, Kim IJ. Cerebral glucose metabolism differs according to future weight change. Brain Imaging Behav 2020;14:2295-2301
- 8. Lin F, Lo RY, Cole D, Ducharme S, Chen DG, Mapstone M, Porsteinsson A. Longitudinal effects of metabolic syndrome on Alzheimer and vascular related brain pathology. Dement Geriatr Cogn Dis Extra 2014;4:184-194
- 9. Marano CM, Workman CI, Lyman CH, Kramer E, Hermann CR, Ma Y, Dhawan V, Chaly T, Eidelberg D, Smith GS. The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging. Psychiatry Res 2014;222:84-90 10. Nugent S, Croteau E, Pifferi F, Fortier M, Tremblay S, Turcotte E, Cunnane SC. Brain and systemic glucose metabolism in the healthy elderly following fish oil supplementation. Prostaglandins Leukot Essent Fatty Acids 2011;85:287-291
- 11. Volkow ND, Wang GJ, Telang F, Fowler JS, Goldstein RZ, Alia-Klein N, Logan J, Wong C, Thanos PK, Ma Y, Pradhan K. Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity (Silver Spring) 2009;17:60-65
- 12. Walters MJ, Sterling J, Quinn C, Ganzer C, Osorio RS, Andrews RD, Matthews DC, Vallabhajosula S, de Leon MJ, Isaacson RS, Mosconi L. Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open 2018;8:e023664
- 13. Wang GJ, Volkow ND, Telang F, Jayne M, Ma Y, Pradhan K, Zhu W, Wong CT, Thanos PK, Geliebter A, Biegon A, Fowler JS. Evidence of gender differences in the ability to inhibit brain activation elicited by food stimulation. Proc Natl Acad Sci U S A 2009;106:1249-1254
- 14. Zhao J, Xue Q, Chen X, You Z, Wang Z, Yuan J, Liu H, Hu L. Evaluation of SUVlean consistency in FDG and PSMA PET/MR with Dixon-, James-, and Janma-based lean body mass correction. EJNMMI Phys 2021;8:17
- 15. Jiang D, Feng H, Qiu X, Zhang Y. 18F-FDG PET/CT in evaluation of glucose metabolism change in prediabetes patients' brain. 2016;32:1184-1188
- 16. Diamanti K, Visvanathar R, Pereira MJ, Cavalli M, Pan G, Kumar C, Skrtic S, Risérus U, Eriksson JW, Kullberg J, Komorowski J, Wadelius C, Ahlström H. Integration of whole-body

- [(18)F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. Sci Rep 2020;10:8343
- 17. García-Casares N, García-Arnés JA, Rioja J, Ariza MJ, Gutiérrez A, Alfaro F, Nabrozidis A, González-Alegre P, González-Santos P. Alzheimer's like brain changes correlate with low adiponectin plasma levels in type 2 diabetic patients. J Diabetes Complications 2016;30:281-286
- 18. Haider A, Bengs S, Diggelmann F, Epprecht G, Etter D, Beeler AL, Wijnen WJ, Treyer V, Portmann A, Warnock GI, Grämer M, Todorov A, Fuchs TA, Pazhenkottil AP, Buechel RR, Tanner FC, Kaufmann PA, Gebhard C, Fiechter M. Age- and sex-dependent changes of resting amygdalar activity in individuals free of clinical cardiovascular disease. J Nucl Cardiol 2021;28:427-432
- 19. Ishai A, Osborne MT, Tung B, Wang Y, Hammad B, Patrich T, Oberfeld B, Fayad ZA, Giles JT, Lo J, Shin LM, Grinspoon SK, Koenen KC, Pitman RK, Tawakol A. Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity. J Clin Endocrinol Metab 2019;104:1029-1038
- 20. Osborne MT, Naddaf N, Abohashem S, Radfar A, Ghoneem A, Dar T, Wang Y, Patrich T, Oberfeld B, Tung B, Pitman RK, Mehta NN, Shin LM, Lo J, Rajagopalan S, Koenen KC, Grinspoon SK, Fayad ZA, Tawakol A. A neurobiological link between transportation noise exposure and metabolic disease in humans. Psychoneuroendocrinology 2021;131:105331
- 21. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, Alexoff D, Ding YS, Wong C, Ma Y, Pradhan K. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage 2008;42:1537-1543
- 22. Wang GJ, Yang J, Volkow ND, Telang F, Ma Y, Zhu W, Wong CT, Tomasi D, Thanos PK, Fowler JS. Gastric stimulation in obese subjects activates the hippocampus and other regions involved in brain reward circuitry. Proc Natl Acad Sci U S A 2006;103:15641-15645
- 23. Mendes A, Tezenas du Montcel S, Levy M, Bertrand A, Habert MO, Bertin H, Dubois B, Epelbaum S. Multimorbidity Is Associated with Preclinical Alzheimer's Disease Neuroimaging Biomarkers. Dement Geriatr Cogn Disord 2018;45:272-281
- 24. Henriksen OM, Birch KJ, Law I. Image quality in brain ¹⁸F-Fluor-Deoxyglucose positron emission tomography: Effects of diabetes, blood glucose and body weight. European Journal of Nuclear Medicine and Molecular Imaging 2014;2):S617
- 25. Mendes A, Du Montcel ST, Cavedo E, Lista S, Hampel H, Dubois B, Epelbaum S. Association of multimorbidity with neurodegeneration and brain amyloid load in cognitively normal subjects. Alzheimer's and Dementia 2017;13(7):P567-P568
- 26. Park Y, Hong S, Choi H, Nam H, Kim Y. Cognitive dysfunction and albuminuria. Diabetes 2012;1):A201-A202
- 27. Pak K, Kim SJ, Kim IJ. Obesity and Brain Positron Emission Tomography. Nucl Med Mol Imaging 2018;52:16-23
- 28. Blautzik J, Kotz S, Brendel M, Sauerbeck J, Vettermann F, Winter Y, Bartenstein P, Ishii K, Rominger A. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment. J Alzheimers Dis 2018;65:781-791
- 29. Malpetti M, Sala A, Vanoli EG, Gianolli L, Luzi L, Perani D. Unfavourable gender effect of high body mass index on brain metabolism and connectivity. Sci Rep 2018;8:12584
- 30. Pegueroles J, Pané A, Vilaplana E, Montal V, Bejanin A, Videla L, Carmona-Iragui M, Barroeta I, Ibarzabal A, Casajoana A, Alcolea D, Valldeneu S, Altuna M, de Hollanda A, Vidal J, Ortega E, Osorio R, Convit A, Blesa R, Lleó A, Fortea J, Jiménez A. Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. Alzheimers Dement (Amst) 2020;12:e12052

- 31. Sala A, Malpetti M, Ferrulli A, Gianolli L, Luzi L, Perani D. High body mass index, brain metabolism and connectivity: an unfavorable effect in elderly females. Aging (Albany NY) 2019:11:8573-8586
- 32. Sundermann EE, Thomas KR, Bangen KJ, Weigand AJ, Eppig JS, Edmonds EC, Wong CG, Bondi MW, Delano-Wood L. Prediabetes Is Associated With Brain Hypometabolism and Cognitive Decline in a Sex-Dependent Manner: A Longitudinal Study of Nondemented Older Adults. Front Neurol 2021;12:551975
- 33. Willette AA, Modanlo N, Kapogiannis D. Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes 2015;64:1933-1940
- 34. Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW. Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. Horm Metab Res 2018;50:627-639
- 35. Johansson E, Lubberink M, Heurling K, Eriksson JW, Skrtic S, Ahlström H, Kullberg J. Whole-Body Imaging of Tissue-specific Insulin Sensitivity and Body Composition by Using an Integrated PET/MR System: A Feasibility Study. Radiology 2018;286:271-278
- 36. García-Casares N, Jorge RE, García-Arnés JA, Acion L, Berthier ML, Gonzalez-Alegre P, Nabrozidis A, Gutiérrez A, Ariza MJ, Rioja J, González-Santos P. Cognitive dysfunctions in middle-aged type 2 diabetic patients and neuroimaging correlations: a cross-sectional study. J Alzheimers Dis 2014;42:1337-1346
- 37. Képes Z, Aranyi C, Forgács A, Nagy F, Kukuts K, Esze R, Somodi S, Káplár M, Varga J, Emri M, Garai I. Homocysteine-related alterations of (18)F-FDG brain pattern in metabolic diseases. Hell J Nucl Med 2021;24:222-227
- 38. Rebelos E, Honka MJ, Ekblad L, Bucci M, Hannukainen JC, Fernandes Silva L, Virtanen KA, Nummenmaa L, Nuutila P. The Obesity Risk SNP (rs17782313) near the MC4R Gene Is Not Associated with Brain Glucose Uptake during Insulin Clamp-A Study in Finns. J Clin Med 2021:10
- 39. Rebelos E, Bucci M, Karjalainen T, Oikonen V, Bertoldo A, Hannukainen JC, Virtanen KA, Latva-Rasku A, Hirvonen J, Heinonen I, Parkkola R, Laakso M, Ferrannini E, Iozzo P, Nummenmaa L, Nuutila P. Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort. Diabetes Care 2021;44:788-794
- 40. Rebelos E, Mari A, Bucci M, Honka MJ, Hannukainen JC, Virtanen KA, Hirvonen J, Nummenmaa L, Heni M, Iozzo P, Ferrannini E, Nuutila P. Brain substrate metabolism and β-cell function in humans: A positron emission tomography study. Endocrinol Diabetes Metab 2020;3:e00136
- 41. Rebelos E, Immonen H, Bucci M, Hannukainen JC, Nummenmaa L, Honka MJ, Soinio M, Salminen P, Ferrannini E, Iozzo P, Nuutila P. Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up. Diabetes Obes Metab 2019;21:218-226
- 42. Edlund AK, Chen K, Lee W, Protas H, Su Y, Reiman E, Caselli R, Nielsen HM. Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE $\epsilon 3/\epsilon 4$ Carriers. J Alzheimers Dis 2021;81:339-354
- 43. Hunt KF, Dunn JT, le Roux CW, Reed LJ, Marsden PK, Patel AG, Amiel SA. Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study. Diabetes Care 2016;39:1787-1795

- 44. Ishibashi K, Kawasaki K, Ishiwata K, Ishii K. Reduced uptake of 18F-FDG and 15O-H2O in Alzheimer's disease-related regions after glucose loading. J Cereb Blood Flow Metab 2015:35:1380-1385
- 45. Ishibashi K, Wagatsuma K, Ishiwata K, Ishii K. Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading. Hum Brain Mapp 2016;37:2823-2832
- 46. Li CT, Bai YM, Hsieh JC, Lee HC, Yang BH, Chen MH, Lin WC, Tsai CF, Tu PC, Wang SJ, Su TP. Peripheral and central glucose utilizations modulated by mitochondrial DNA 10398A in bipolar disorder. Psychoneuroendocrinology 2015;55:72-80
- 47. Li Q, Jin R, Yu H, Lang H, Cui Y, Xiong S, Sun F, He C, Liu D, Jia H, Chen X, Chen S, Zhu Z. Enhancement of Neural Salty Preference in Obesity. Cell Physiol Biochem 2017;43:1987-2000
- 48. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, Larson SM, Roth J. Brain glucose metabolism in noninsulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic glucose clamp. J Clin Endocrinol Metab 1990;71:1602-1610
- 49. Ennis GE, Kohli A, Jonaitis EM, Betthauser TJ, Oh JM, Taylor CE, Chin N, Koscik RL, Christian BT, Asthana S, Johnson SC, Bendlin BB. The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiol Aging 2021;105:174-185
- 50. Kantonen T, Pekkarinen L, Karjalainen T, Bucci M, Kalliokoski K, Haaparanta-Solin M, Aarnio R, Dickens AM, von Eyken A, Laitinen K, Houttu N, Kirjavainen AK, Helin S, Hirvonen J, Rönnemaa T, Nuutila P, Nummenmaa L. Obesity risk is associated with altered cerebral glucose metabolism and decreased μ -opioid and CB(1) receptor availability. Int J Obes (Lond) 2022;46:400-407
- 51. Wang GJ, Shokri Kojori E, Yuan K, Wiers CE, Manza P, Wong CT, Fowler JS, Volkow ND. Inhibition of food craving is a metabolically active process in the brain in obese men. Int J Obes (Lond) 2020;44:590-600
- 52. Almby KE, Lundqvist MH, Abrahamsson N, Kvernby S, Fahlström M, Pereira MJ, Gingnell M, Karlsson FA, Fanni G, Sundbom M, Wiklund U, Haller S, Lubberink M, Wikström J, Eriksson JW. Effects of Gastric Bypass Surgery on the Brain: Simultaneous Assessment of Glucose Uptake, Blood Flow, Neural Activity, and Cognitive Function During Normo- and Hypoglycemia. Diabetes 2021;70:1265-1277
- 53. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK, Amiel SA. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006;55:2986-2992
- 54. Osborne MT, Ishai A, Hammad B, Tung B, Wang Y, Baruch A, Fayad ZA, Giles JT, Lo J, Shin LM, Grinspoon SK, Koenen KC, Pitman RK, Tawakol A. Amygdalar activity predicts future incident diabetes independently of adiposity. Psychoneuroendocrinology 2019;100:32-40